Lumira Ventures
Lumira Ventures is a venture capital firm that specializes in investing in emerging, mid, and late-stage companies within the healthcare and life sciences sectors. Founded in 2007 and based in Toronto, Ontario, with additional offices in Montreal, Vancouver, and Boston, the firm primarily focuses on biotechnology, biopharmaceuticals, medical devices, digital health, and consumer health companies. Lumira Ventures typically invests between 5 million and 15 million in North American companies, emphasizing those located in Canada and the United States. The firm is committed to helping its portfolio companies enhance the value of their technology pipelines through active board participation and support in accessing additional funding sources and market opportunities. With a history that includes investments in over 100 healthcare companies, Lumira Ventures currently manages a portfolio of more than 30 active investee companies that aim to address significant unmet needs in the healthcare landscape.
enGene, Inc. is a biotechnology company based in Vancouver, Canada, focused on developing a mucosal immunotherapy platform aimed at treating inflammatory bowel disease and diabetes. The company utilizes a non-integrating biopolymer-based nucleotide delivery technology, which allows for the localized delivery of immune-modulating proteins to the intestinal mucosa. This innovative approach targets diseases affecting mucosal tissues, including those in the gastrointestinal tract, lung, and bladder, while also facilitating systemic protein release to address conditions such as diabetes, anemia, and hemophilia. enGene’s platform technology supports the induction or suppression of protein expression levels, enabling improved physiological insulin secretion in diabetes patients. The company has established a strategic alliance with Takeda Pharmaceutical Company Ltd. since its founding in 1999.
Zymeworks Inc. is a clinical-stage biopharmaceutical company based in Vancouver, Canada, that specializes in the discovery, development, and commercialization of biotherapeutics, primarily for cancer treatment. The company’s leading candidates include ZW25, a bispecific antibody currently undergoing Phase I and II clinical trials targeting various cancers, and ZW49, a bispecific antibody-drug conjugate in Phase I trials for advanced HER2-expressing cancers. Zymeworks employs advanced computational biotechnology techniques, utilizing proprietary molecular modeling and high-performance computing to optimize therapeutic antibodies and other protein-based therapeutics. The company has established strategic partnerships and collaborations with several major pharmaceutical firms, including Merck, Eli Lilly, and Bristol-Myers Squibb, among others, to enhance its research and development efforts. Founded in 2003, Zymeworks continues to focus on developing innovative solutions for cancer and other serious diseases.
enGene, Inc. is a biotechnology company based in Vancouver, Canada, focused on developing a mucosal immunotherapy platform aimed at treating inflammatory bowel disease and diabetes. The company utilizes a non-integrating biopolymer-based nucleotide delivery technology, which allows for the localized delivery of immune-modulating proteins to the intestinal mucosa. This innovative approach targets diseases affecting mucosal tissues, including those in the gastrointestinal tract, lung, and bladder, while also facilitating systemic protein release to address conditions such as diabetes, anemia, and hemophilia. enGene’s platform technology supports the induction or suppression of protein expression levels, enabling improved physiological insulin secretion in diabetes patients. The company has established a strategic alliance with Takeda Pharmaceutical Company Ltd. since its founding in 1999.
enGene, Inc. is a biotechnology company based in Vancouver, Canada, focused on developing a mucosal immunotherapy platform aimed at treating inflammatory bowel disease and diabetes. The company utilizes a non-integrating biopolymer-based nucleotide delivery technology, which allows for the localized delivery of immune-modulating proteins to the intestinal mucosa. This innovative approach targets diseases affecting mucosal tissues, including those in the gastrointestinal tract, lung, and bladder, while also facilitating systemic protein release to address conditions such as diabetes, anemia, and hemophilia. enGene’s platform technology supports the induction or suppression of protein expression levels, enabling improved physiological insulin secretion in diabetes patients. The company has established a strategic alliance with Takeda Pharmaceutical Company Ltd. since its founding in 1999.